Clinical Protocol For A Phase II Double-Blind, Placebo-Controlled, Randomized Study Of Celecoxib (Sc-58635) In Oral Premalignant Lesions, Investigator IND

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Outcome Measure:

To evaluate the efficacy of celecoxib in subjects with Early or Advanced oral premalignant lesion (OPL)

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

NQ4-00-02-011

NCT ID:

NCT00036283

Start Date:

November 2000

Completion Date:

April 2004

Related Keywords:

• Precancerous Conditions
• Precancerous Conditions